ENZAMET shows promise as prostate cancer treatment
A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates.
The results from the clinical trial of ENZAMET, co-chaired by Professor Christopher Sweeney, Director of the South ÐÓ°ÉÖ±²¥n immunoGENomics Cancer Institute (SAiGENCI) that operates within the ÐÓ°ÉÖ±²¥ of Adelaide, have been published today in .